Danielle Sara Bitterman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Natural Language Processing | 7 | 2024 | 1041 | 2.260 |
Why?
|
Radiation Oncology | 5 | 2023 | 555 | 2.100 |
Why?
|
Artificial Intelligence | 7 | 2023 | 2214 | 1.560 |
Why?
|
Neoplasms | 12 | 2023 | 21683 | 1.010 |
Why?
|
Language | 2 | 2024 | 1471 | 0.980 |
Why?
|
Esophagitis | 1 | 2023 | 152 | 0.830 |
Why?
|
Germinoma | 1 | 2019 | 133 | 0.660 |
Why?
|
Medical Informatics | 2 | 2022 | 745 | 0.650 |
Why?
|
Pineal Gland | 1 | 2019 | 166 | 0.640 |
Why?
|
Equipment and Supplies | 1 | 2020 | 281 | 0.600 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2020 | 2214 | 0.590 |
Why?
|
Equipment Failure | 1 | 2018 | 578 | 0.540 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 7 | 2022 | 5221 | 0.540 |
Why?
|
Brain Neoplasms | 3 | 2024 | 8863 | 0.530 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2021 | 806 | 0.510 |
Why?
|
Liver Neoplasms | 2 | 2020 | 4253 | 0.460 |
Why?
|
Esophageal Neoplasms | 1 | 2023 | 1583 | 0.450 |
Why?
|
Pacemaker, Artificial | 1 | 2018 | 816 | 0.440 |
Why?
|
Androgen Antagonists | 1 | 2021 | 1377 | 0.420 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2022 | 2915 | 0.400 |
Why?
|
Lung Neoplasms | 8 | 2022 | 13102 | 0.400 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2022 | 2916 | 0.400 |
Why?
|
Radiotherapy | 1 | 2018 | 1533 | 0.390 |
Why?
|
Prostate-Specific Antigen | 1 | 2021 | 2494 | 0.390 |
Why?
|
Central Nervous System Neoplasms | 1 | 2019 | 895 | 0.380 |
Why?
|
Clinical Trials as Topic | 3 | 2023 | 7913 | 0.380 |
Why?
|
Testosterone | 1 | 2021 | 2420 | 0.370 |
Why?
|
Embolization, Therapeutic | 1 | 2019 | 1392 | 0.340 |
Why?
|
Defibrillators, Implantable | 1 | 2018 | 1440 | 0.340 |
Why?
|
Medical Oncology | 5 | 2023 | 2265 | 0.290 |
Why?
|
Thrombosis | 1 | 2020 | 2968 | 0.270 |
Why?
|
Palliative Care | 1 | 2020 | 3493 | 0.250 |
Why?
|
Glioma | 1 | 2019 | 3401 | 0.240 |
Why?
|
Humans | 42 | 2024 | 744343 | 0.240 |
Why?
|
Heart Diseases | 3 | 2022 | 2788 | 0.230 |
Why?
|
Informatics | 1 | 2023 | 72 | 0.220 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 9959 | 0.220 |
Why?
|
Radiation Dosage | 6 | 2022 | 1928 | 0.220 |
Why?
|
Silver | 1 | 2023 | 122 | 0.220 |
Why?
|
Pancreatic Neoplasms | 1 | 2020 | 5256 | 0.220 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5319 | 0.210 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5751 | 0.200 |
Why?
|
Fund Raising | 1 | 2021 | 47 | 0.200 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7279 | 0.190 |
Why?
|
Neutrons | 1 | 2018 | 76 | 0.160 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11124 | 0.160 |
Why?
|
Social Environment | 1 | 2023 | 1023 | 0.150 |
Why?
|
Stereotaxic Techniques | 1 | 2020 | 536 | 0.150 |
Why?
|
Coronary Vessels | 4 | 2022 | 3107 | 0.150 |
Why?
|
Informed Consent | 1 | 2023 | 995 | 0.140 |
Why?
|
Electronic Health Records | 3 | 2023 | 4468 | 0.140 |
Why?
|
Radiation Tolerance | 1 | 2018 | 486 | 0.140 |
Why?
|
Physicians, Primary Care | 1 | 2022 | 591 | 0.130 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2015 | 1519 | 0.130 |
Why?
|
Proportional Hazards Models | 2 | 2020 | 12354 | 0.130 |
Why?
|
Radiotherapy Dosage | 1 | 2021 | 2879 | 0.130 |
Why?
|
Retrospective Studies | 10 | 2023 | 77449 | 0.120 |
Why?
|
Prednisolone | 1 | 2015 | 334 | 0.120 |
Why?
|
Data Mining | 1 | 2019 | 537 | 0.120 |
Why?
|
Male | 15 | 2023 | 350118 | 0.120 |
Why?
|
Medicine | 1 | 2022 | 946 | 0.120 |
Why?
|
Androgens | 1 | 2021 | 1281 | 0.110 |
Why?
|
Fellowships and Scholarships | 1 | 2021 | 1076 | 0.110 |
Why?
|
Pyrimidinones | 1 | 2015 | 371 | 0.110 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2021 | 1624 | 0.110 |
Why?
|
Mediastinal Neoplasms | 1 | 2016 | 423 | 0.110 |
Why?
|
Receptors, Glucocorticoid | 1 | 2014 | 302 | 0.110 |
Why?
|
Propensity Score | 1 | 2019 | 1781 | 0.110 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1584 | 0.100 |
Why?
|
Anus Neoplasms | 1 | 2015 | 332 | 0.100 |
Why?
|
Radiation Injuries | 1 | 2019 | 1180 | 0.100 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2016 | 332 | 0.100 |
Why?
|
Brachytherapy | 1 | 2019 | 1248 | 0.100 |
Why?
|
Pyridones | 1 | 2015 | 712 | 0.090 |
Why?
|
Heart | 2 | 2021 | 4467 | 0.090 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2015 | 5172 | 0.090 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 871 | 0.090 |
Why?
|
Proteomics | 1 | 2022 | 3638 | 0.090 |
Why?
|
Rectal Neoplasms | 1 | 2018 | 1206 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6538 | 0.080 |
Why?
|
Female | 14 | 2023 | 380194 | 0.080 |
Why?
|
MAP Kinase Signaling System | 1 | 2015 | 1526 | 0.080 |
Why?
|
Neoplasm Staging | 2 | 2019 | 11031 | 0.080 |
Why?
|
Neoadjuvant Therapy | 1 | 2018 | 2728 | 0.080 |
Why?
|
Software | 1 | 2021 | 4443 | 0.070 |
Why?
|
Aged | 7 | 2021 | 163280 | 0.070 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2015 | 1873 | 0.070 |
Why?
|
Genomics | 1 | 2022 | 5720 | 0.070 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 3255 | 0.070 |
Why?
|
Middle Aged | 7 | 2021 | 213383 | 0.070 |
Why?
|
Survival Rate | 1 | 2019 | 12788 | 0.060 |
Why?
|
Databases, Factual | 1 | 2019 | 7729 | 0.060 |
Why?
|
Physicians | 1 | 2021 | 4567 | 0.060 |
Why?
|
Quality Improvement | 1 | 2018 | 3749 | 0.060 |
Why?
|
Repressor Proteins | 1 | 2014 | 3023 | 0.060 |
Why?
|
Chromatin | 1 | 2014 | 2934 | 0.050 |
Why?
|
Coronary Artery Disease | 1 | 2022 | 6487 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 12804 | 0.050 |
Why?
|
Neoplasm Proteins | 1 | 2014 | 3703 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8480 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2022 | 288 | 0.050 |
Why?
|
United States | 4 | 2022 | 69872 | 0.050 |
Why?
|
Electronics | 1 | 2022 | 322 | 0.050 |
Why?
|
Gene Knockdown Techniques | 2 | 2015 | 1655 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2015 | 4034 | 0.040 |
Why?
|
Prognosis | 1 | 2020 | 29063 | 0.040 |
Why?
|
Prospective Studies | 2 | 2021 | 53288 | 0.040 |
Why?
|
Nuclear Proteins | 1 | 2014 | 5853 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6364 | 0.040 |
Why?
|
Models, Biological | 1 | 2014 | 9583 | 0.040 |
Why?
|
Angina Pectoris | 1 | 2021 | 977 | 0.040 |
Why?
|
Myocardial Revascularization | 1 | 2021 | 841 | 0.040 |
Why?
|
Information Storage and Retrieval | 1 | 2022 | 824 | 0.040 |
Why?
|
Death | 1 | 2021 | 678 | 0.030 |
Why?
|
Child | 3 | 2019 | 77709 | 0.030 |
Why?
|
Colostomy | 1 | 2015 | 99 | 0.030 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2015 | 96 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2019 | 63114 | 0.030 |
Why?
|
MAP Kinase Kinase 4 | 1 | 2015 | 148 | 0.030 |
Why?
|
Gender Identity | 1 | 2021 | 688 | 0.030 |
Why?
|
Standard of Care | 1 | 2019 | 564 | 0.030 |
Why?
|
Aged, 80 and over | 1 | 2020 | 57776 | 0.030 |
Why?
|
Watchful Waiting | 1 | 2018 | 492 | 0.030 |
Why?
|
Faculty, Medical | 1 | 2021 | 1181 | 0.030 |
Why?
|
Remission Induction | 1 | 2018 | 2386 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 35421 | 0.030 |
Why?
|
Patient Selection | 1 | 2022 | 4215 | 0.020 |
Why?
|
Histone Deacetylases | 1 | 2014 | 728 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2022 | 3528 | 0.020 |
Why?
|
HIV Infections | 1 | 2015 | 16718 | 0.020 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2014 | 789 | 0.020 |
Why?
|
Calcium | 1 | 2022 | 5756 | 0.020 |
Why?
|
Child, Preschool | 3 | 2016 | 41006 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2015 | 16689 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 4751 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8663 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2864 | 0.020 |
Why?
|
Sex Factors | 1 | 2021 | 10397 | 0.020 |
Why?
|
Logistic Models | 1 | 2022 | 13408 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2015 | 3557 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 40561 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 4186 | 0.020 |
Why?
|
Research Design | 1 | 2022 | 5987 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39050 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2019 | 3843 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2015 | 2948 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2014 | 2107 | 0.020 |
Why?
|
Survival Analysis | 1 | 2015 | 10252 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 20947 | 0.010 |
Why?
|
Genome, Human | 1 | 2016 | 4420 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12245 | 0.010 |
Why?
|
Algorithms | 1 | 2022 | 13881 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16365 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2021 | 11727 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2015 | 21746 | 0.010 |
Why?
|
Heart Failure | 1 | 2021 | 10900 | 0.010 |
Why?
|
Adolescent | 2 | 2015 | 85781 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2015 | 12261 | 0.010 |
Why?
|
Risk Factors | 1 | 2022 | 72290 | 0.010 |
Why?
|
Adult | 2 | 2021 | 214055 | 0.010 |
Why?
|
Mice | 1 | 2015 | 81183 | 0.000 |
Why?
|
Animals | 1 | 2015 | 168757 | 0.000 |
Why?
|